Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 285

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Guidelines for good pharmacoepidemiology practice (GPP)

Open access
Public Policy Committee, International Society of Pharmacoepidemiology·2016·Pharmacoepidemiology and Drug Safety

Abstract

Pharmacoepidemiologic studies provide valuable information about the health effects of healthcare products. The ISPE Guidelines for Good Pharmacoepidemiology Practice (GPP) are intended to assist investigators with issues pertaining to the planning, conduct, and interpretation of pharmacoepidemiologic research. This paper represents the fourth version and supersedes previous versions. While the overall structure and nature of the GPP has been preserved in the current revision, new sections have been added, and the text has been updated to reflect current practice. Pharmacoepidemiology is being used increasingly to evaluate health care systems, interventions, and health-related behaviors. Pharmacoepidemiology is the scientific backbone of therapeutic risk management—the process of assessing a product's benefits and risks, and developing, implementing, and evaluating strategies to enhance the overall balance of such benefits and risks. Pharmacoepidemiology is also the scientific backbone of comparative effectiveness research (CER). These guidelines are intended to address these activities and other pharmacoepidemiologic studies. The GPP propose essential practices and procedures that should be considered to help ensure the quality and integrity of pharmacoepidemiologic research and to provide adequate documentation of research methods and results. The GPP do not prescribe specific research methods nor will adherence to guidelines guarantee valid research. The GPP are intended to apply broadly to all types of pharmacoepidemiologic research, including feasibility assessments, validation studies, descriptive studies, and etiologic investigations, and all of their related activities from design through publication. Therapeutic risk management activities provide a formal framework in which medicine, pharmacoepidemiology, and public health are integrated in the development and life-cycle management of healthcare products. Pharmacoepidemiology is the core science of risk assessment and the evaluation of the effectiveness of risk minimization interventions. Therefore, the GPP also support risk management activities. In a similar fashion, pharmacoepidemiology is the core discipline of CER. Such activities are based on problems from clinical medicine, by using rigorous methods to compare the outcomes of two or more therapeutic alternatives. Thereby, comparative effectiveness activities are defined by their research questions rather than by their methods. a statement of research objectives, specific aims, and rationale; Research objectives describe the knowledge or information to be gained from the study. Specific aims list key exposures and outcomes of interest, and any hypotheses to be evaluated. The protocol should distinguish between a limited number of a priori research hypotheses and hypotheses that are generated based on knowledge of the source data. The rationale explains how achievement of the specific aims will further the research objectives. The research question may be phrased by using the PICOT template; population, intervention, comparator, outcome, and timing. a critical review of the literature to evaluate pertinent information and gaps in knowledge; The literature review should describe specific gaps in knowledge that the study is intended to fill. The literature review might encompass relevant animal and human experiments, clinical studies, vital statistics, and previous epidemiologic studies. The literature review should also cite the findings of similar studies, and the expected contribution of the current study. the overall research design and reasons for choosing the proposed study design; Research designs include, for example, case–control, cohort, cross-sectional, nested case–control, self-controlled, randomized trials or hybrid designs. Any feasibility or pilot work that informed the choice of design should be described here. the population or sample to be studied; The population is defined in terms of persons, place, time period, and selection criteria. The rationale for the inclusion and exclusion criteria and their impact on the number of subjects available for analysis should be described, if known. If any sampling from a defined population is undertaken, description of the population and details of sampling methods should be provided. Some justification should be given to support that the necessary study size is actually attainable from the given data source or design. This could be data from informal queries or pilot studies. Considerations of generalizability from the study population to those actually receiving the drug may be voiced here. the strategies and data sources for determining exposures, health outcomes, and all other variables relevant to the study objectives, such as potential confounding variables and effect measure modifiers; Data sources might include, for example, questionnaires, hospital discharge files, abstracts of primary clinical records, clinical databases, electro

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.3891

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 285

Metadata

Authors
Public Policy Committee, I. S. O. P.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2015-11-05
Volume
25
Issue
1
Pages
2-10
ISSN
1053-8569 (ISSN-L)
OpenAlex
W4232249876
Cited by
285
References
1
FWCI
13.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for good pharmacoepidemiology practice (GPP). https://app.cochat.ai/papers/10.1002/pds.3891
The paper
Public Policy Committee, I. S. O. P. (2016). Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.3891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.